| [1] Peet R I, Coackley W, Purcell D A, et al. Adenovirus inclusions in sheep liver. Aust Vet J,1983,60(10):307-308.
[2] Benko M, Harrach B. A proposal for a new (third) genus within the family Adenoviridae. Arch Virol,1998,143(4):829-837.
[3] Fauquet C M, Mayo M A, Maniloff J, et al. Virus taxonomy, 8th report of the international committee on taxonomy of viruses. California: Virology division international union of microbiological societies. Elsevier Academic Press, 2005.
[4] Khatri A, Both G W. Identification of transcripts and promoter regions of ovine adenovirus OAV287. Virology, 1998,245(1):128-141.
[5] Davison A, Benko M, Harrach B. Genetic content and evolution of adenoviruses. Journal of General Virology, 2003,84:2895-2908.
[6] Gorman J J, Wallis T P, Whelan D A, et al. LH3, a "homologue" of the mastadenoviral E1B 55-kDa protein is a structural protein of atadenoviruses. Virology, 2005,342(1):159-166.
[7] Vrati S, Boyle D, Kocherhans R, et al. Sequence of ovine adenovirus homologs for 100K hexon assembly, 33K, pVIII, and fiber genes: early region E3 is not in the expected location. Virology, 1995,209(2): 400-408.
[8] Vrati S, Brookes D E, Strike P, et al. Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites. Virology, 1996, 220(1):186-199.
[9] Kümin D, Hofmann C, Uckert W, et al. Identification of an ovine atadenovirus gene whose product activates the viral E2 promoter: possible involvement of E2F-1. Virology, 2004,318(1):79-89.
[10] Both G W. Identification of a unique family of F-box proteins in atadenoviruses. Virology, 2002, 304(2): 425-433.
[11] Xu Z Z, Hyatt A, Boyle D B, et al. Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virology, 1997,230(1): 62-71.
[12] Gerald W B. Ovine atadenovirus: a review of its biology, biosafety pro?le and application as a gene delivery vector. Immunology and Cell Biology, 2004,82(2):189-195.
[13] Venktesh A, Fujiko W, Both G W, et al. Ovine adenovirus (OAV287) lacks a virus-associated RNA gene. Journal of General Virology, 1998,79:509-516 .
[14] Anurag S, Xiaoxin L, Dinesh S B, et al. Adenovirus receptors and their implications in gene delivery. Virus Research, 2009,143(2):184-194.
[15] Edelstein M L, Abedi M R, Wixon J, et al. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med, 2004,6(6):597-602.
[16] Thacker E E, Timares L, Matthews Q L. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines, 2009,8(6):761-777.
[17] Dinesh S B, Suresh K M. Development of nonhuman adenoviruses as vaccine vectors. Vaccine, 2006,24(7): 849-862.
[18] Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol, 2004,11(2):351-357.
[19] Barouch D H, Nabel G J. Adenovirus vector-based vaccines for human immunode?ciency virus type 1. Hum Gene Ther, 2005,16(2):149-156.
[20] Zaiss A K, Machado H B, Herschman H R. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem, 2009,108(4):778-790.
[21] Sharma A, Dinesh S B, Tandon M, et al. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology, 2009, 386(1): 44-54.
[22] Hofmann C, Loser P, Cichon G, et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol, 1999,73(8):6930-6936.
[23] Peter L, Günter C, Gary S J, et al. Ovine adenovirus vectors promote efficient gene delivery in vivo. Gene Ther Mol Biol, 1999,4:33-43.
[24] Russell W C. Adenoviruses: update on structure and function. J Gen Virol, 2009, 90:1-20.
[25] Joanna L H , Youn B L, James B, et al. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol, 2010, 26(1):1-20.
[26] Kalyuzhniy O, Di Paolo N C, Silvestry M, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA, 2008,105(14):5483-5488.
[27] Xu Z Z, Both G W. Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5. Virology, 1998,248(1):156-163.
[28] Loser P, Hillgenberg M, Arnold W, et al. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther, 2000,7(17):1491-1498.
[29] Kumin D, Hofmann C, Rudolph M, et al. Biology of ovine adenovirus infection of nonpermissive cells. J Virol, 2002,76(21):10882-10893.
[30] Lockett L J, Both G W. Complementation of a defective human adenovirus by an otherwise incompatible ovine adenovirus recombinant carrying a functional E1A gene. Virology, 2002, 294(2):333-341.
[31] Voeks D, Martiniello-Wilks R, Madden V, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and ?udarabine in mouse models. Gene Ther, 2002,9(12):759-768.
[32] Martiniello-Wilks R, Dane A, Voeks D J, et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med, 2004,6(1):43-54.
[33] Wuest T, Both G W, Prince A M, et al. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine, 2004,22(21-22):2717-2721.
[34] Bridgeman A, Roshorm Y, Lockett L J, et al. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine, 2010, 28(2):474-483. |
